Histogenics Corp. (NASDAQ:HSGX) shares shot up 30.2% on Monday . The stock traded as high as $2.97 and last traded at $2.76, with a volume of 58,985 shares. The stock had previously closed at $2.12.

Several research firms have weighed in on HSGX. BTIG Research upgraded Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 target price on the stock in a report on Thursday. Canaccord Genuity reiterated a “buy” rating on shares of Histogenics Corp. in a report on Thursday, May 12th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Histogenics Corp. currently has an average rating of “Buy” and an average price target of $9.75.

The stock’s market cap is $37.43 million. The company’s 50 day moving average price is $1.90 and its 200 day moving average price is $2.19.

Histogenics Corp. (NASDAQ:HSGX) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.01. During the same period in the prior year, the business posted ($0.58) EPS. Equities research analysts anticipate that Histogenics Corp. will post ($2.11) EPS for the current year.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.